includ derm updat model
messag earn updat model reflect recent
acquisit derm cash deal per share expect
transact close within next sever week prior end
expect new bidder emerg transact look accret earn
driven almost entir sale royalti lebrikizumab moder
sever atop dermat current domin san-par/regn dupix
increas trulic verzenio revenu off-set decreas tradjenta
jardianc revenu remain neutral rate
increas long-term revenu due derm acquisit post earn see
note sale broadli oi tax contribut ep upsid margin
increas revenu estim
respect chang ep estim
respect tax rate
note revenu estim factset consensu estim
ep estim lower consensu
increas revenu due addit revenu lebrikizumab atop
dermat announc acquisit derm expect close
product level key chang decreas tradjenta revenu estim
impact restructur deal boehring ingelheim tradjenta transit
back boehring ingelheim book tradjenta royalti
time basaglar transit back offset royalti reduct tradjenta
inhibitor diabet expect lose exclus increas trulic
revenu due continu momentum market verzenio revenu due
potenti indic adjuv breast cancer set continu momentum
potenti catalyst
compani
page analyst certif import disclosur
pipelin potenti catalystsag moa indicationtrialpotenti catalyststock impactour viewtimingtaltz anti head-to-head vs tremfya ixora-r phase full week data solanezumab anti amyloid ab alzheim diseasephas ii/top-lin result earli inhibitor psoriasisphas oasi inhibitor heart failur -hfrefphas emperor-reducedtop-lin activ enhanc nsclcphase ii fail full result inhibitor ulcer colitisphas lucent receptor type diabetesphas inhibitor heart failur -hfpefphas emperor-preservedtop-lin result late inhibitor alopecia areata sever severephas result late global
valuat risk
fair valu rang reflect forecast sale profit
use larg pharmaceut compani discount rate
upsid risk includ trulic taltz jardianc sale meaning
estim better expect oper leverag
downsid risk includ sustain price pressur diabet immunolog
potenti pricing/deb pressur emgal taltz competit trulic
market novo ozemp rybelsu
page analyst certif import disclosur
usd million except ep
compani report guggenheim llc estim
page analyst certif import disclosur
